Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Peter A, Lio"'
Autor:
Nicholas D. Brownstone, MD, Aaron S. Farberg, MD, Graham H. Litchman, DO, MS, Ann P. Quick, PhD, Jennifer J. Siegel, PhD, Lenka V. Hurton, PhD, Matthew S. Goldberg, MD, Peter A. Lio, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 49-56 (2024)
Background: Empirical decisions to select therapies for psoriasis (PSO) and atopic dermatitis (AD) can lead to delays in disease control and increased health care costs. However, routine molecular testing for AD and PSO are lacking. Objective: To exa
Externí odkaz:
https://doaj.org/article/8f6eb800b6ed4606b5f4e8112290424d
Autor:
Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1929-1943 (2024)
Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient’s quality of life (QoL) and mental health. Here, we assess the impact of lebrikizumab on QoL and me
Externí odkaz:
https://doaj.org/article/f74ec9cd69bd430dbe00e9106d83a5c1
Publikováno v:
JAAD International, Vol 11, Iss , Pp 8-10 (2023)
Externí odkaz:
https://doaj.org/article/80250905a6264beea1d45ad99c2f4bc0
Autor:
Peter A. Lio, Eric L. Simpson, George Han, Jennifer Soung, Susan Ball, Luna Sun, Marta Casillas, Amy M. DeLozier, Yuxin Ding, Lawrence F. Eichenfield
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 4, Pp 2057-2062 (2022)
Background Baricitinib previously demonstrated improvements in itch and sleep disturbance versus placebo in adults with moderate-to-severe atopic dermatitis (AD). Objectives Examine if itch and sleep improvements are associated with better quality of
Externí odkaz:
https://doaj.org/article/9d67b55e9f434fe48055ed0e9f41112f
Autor:
Jonwei Hwang, Peter A. Lio
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 3, Pp 1293-1298 (2022)
Background Topical corticosteroid withdrawal is an entity associated with chronic steroid use and misuse that has not been fully described. Objective To further characterize this entity, elucidate relevant clinical features, and investigate possible
Externí odkaz:
https://doaj.org/article/a2c8f291abac404c8f232b826ff379e2
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 1, Pp 73-86 (2022)
Purpose Anakinra (Kineret®) is an interleukin-1 receptor antagonist (IL-1Ra) FDA approved for use in rheumatoid arthritis and in neonatal-onset multisystem inflammatory disease (NOMID). It has been used off-label for a variety of dermatologic condit
Externí odkaz:
https://doaj.org/article/c62496e3ae734efe85e7f5f16368d380
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 17, p 5534 (2023)
Atopic dermatitis (AD) is a common, chronic and recurring inflammatory skin disorder characterized by an intensely pruritic, eczematous dermatitis. The etiology of AD is thought to involve a combination of environmental, genetic, and immunologic fact
Externí odkaz:
https://doaj.org/article/b9b58387b4524ba3a94965be51ac724e
Autor:
Daniel C. Butler, Eric Simpson, Emma Guttman-Yassky, Lawrence F. Eichenfield, Alexandra K. Golant, John Y. M. Koo, April W. Armstrong, Andrew F. Alexis, Peter A. Lio, Justin W. Marson, Mark Lebwohl
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 4, Pp 2397-2399 (2022)
Externí odkaz:
https://doaj.org/article/aa69b5e4dc494b0f9561a3dc206c17ce
Publikováno v:
Journal of Dermatological Treatment, Vol 32, Iss 5, Pp 503-506 (2021)
Externí odkaz:
https://doaj.org/article/41ec179ad16947ed835652f0e4a2fada
Autor:
Kyle Tegtmeyer, Jeffrey Zhao, Nolan J. Maloney, Giancarlo Atassi, Molly Beestrum, Peter A. Lio
Publikováno v:
Journal of Dermatological Treatment, Vol 32, Iss 4, Pp 399-409 (2021)
Purpose Tofacitinib citrate is an oral Janus kinase 1/3 inhibitor approved for rheumatoid arthritis, ulcerative colitis, and active psoriatic arthritis. Tofacitinib is being increasingly used off-label for dermatological conditions, with varying effi
Externí odkaz:
https://doaj.org/article/61208c408cb744f0be4bab6a430d2d8e